Buy-to-let returns are too low. I’d buy the GlaxoSmithKline share price every time

These figures show why GlaxoSmithKline plc (LON: GSK) is a much better investment than buy-to-let, according to Rupert Hargreaves.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past few decades, buy-to-let as an asset class has created a tremendous amount of wealth for investors. However, more recently, it’s become harder to make money from renting than ever before.

Additional layers of regulation, the withdrawal of certain tax benefits, and the introduction of new stamp duty charges for second home buyers, (up to 15% for homes over £1.5m) means that buy-to-let investing is no longer the sure thing it once was.

Meanwhile, rental yields across the country have been falling and, although some markets still offer potential yields in the 5% to 8% range, when you include costs, returns aren’t as attractive. 

With this being the case, I’m shunning buy-to-let and putting my money in GlaxoSmithKline (LSE: GSK) instead. 

A better buy 

From an investment perspective, shares in Glaxo immediately looks to me to be a better buy than a rental property. 

For a start, buy-to-let is becoming an increasingly hot topic in the political world. A few bad actors have given the industry an awful reputation, and politicians always seem to be looking for ways to make life harder for investors. 

This layer of political uncertainty is enough to scare me away from buy-to-let investing altogether. We just don’t know what the politicians will decide to target next, and trying to sell a property quickly if the rules change could be difficult. 

In comparison, as one of the world’s largest pharmaceutical and consumer healthcare businesses, Glaxo’s fortunes are not tied to the success or failure of one drug or market. If new regulations cause the company’s growth to slow in one market, growth in other regions should offset some of the headwinds. 

Care-free income 

I think this global diversification, and Glaxo’s defensive nature, also makes the company a much better income investment than buy-to-let property. You see, right now shares in this pharmaceutical giant support a dividend yield of 5.4%. This compares to a potential income of 8% from buy-to-let and, as noted above, this is a yield excluding costs.

Including the costs of managing the property you might be lucky to achieve a net return of 5%. But considering all of the work involved in managing a property, I’m not convinced this return is worth it. 

Glaxo’s 5.4% dividend yield is available with no effort required on your part whatsoever. 

Capital gains 

Another major part of buy-to-let returns is the capital appreciation of property. In the past, this part of the equation has provided a more significant return for investors than rental income. The problem is, home price growth in the UK is starting to slow, and it’s starting to look as if capital returns from property will be significantly lower over the next 10 years than in the past decade. 

I’m not saying property prices will fall, but it certainly looks as if the days when property prices increased by 5-10% per annum on average are now long gone. 

Once again, capital growth is something Glaxo might be able to offer where buy-to-let can’t. A combination of earnings growth, coupled with the prospective breakup of the business could, according to my figures, yield a total return for investors of 48% over the next three years, with no extra effort. That looks to me to be a much better deal than buy-to-let.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »